

STAND. COM. REP. NO.

1525

Honolulu, Hawaii

**MAR 25**, 2025

RE: H.C.R. No. 35

Honorable Nadine K. Nakamura  
Speaker, House of Representatives  
Thirty-Third State Legislature  
Regular Session of 2025  
State of Hawaii

Madame:

Your Committee on Health, to which was referred H.C.R. No. 35  
entitled:

"HOUSE CONCURRENT RESOLUTION REQUESTING THE AUDITOR TO ASSESS  
THE SOCIAL AND FINANCIAL EFFECTS OF MANDATORY HEALTH  
INSURANCE COVERAGE FOR BIOMARKER TESTING,"

begs leave to report as follows:

The purpose of this measure is to request the Auditor to  
assess the social and financial effects of mandatory health  
insurance coverage for biomarker testing.

Your Committee received testimony in support of this measure  
from the State Health Planning and Development Agency; Alzheimer's  
Association-Hawaii; Oncology Nursing Society; Hawai'i Parkinson  
Association; Environmental Caucus of the Democratic Party of  
Hawai'i; Liberty Dialysis Hawai'i; American Cancer Society Cancer  
Action Network; a petition signed by over two hundred individuals;  
and nine individuals.

Your Committee finds that biomarker testing is an invaluable  
tool in the diagnosis, treatment, appropriate management, and  
ongoing monitoring of diseases or conditions. Your Committee  
further finds that although the Auditor previously assessed the  
social and financial effects of mandatory health insurance  
coverage for biomarker testing, as proposed by House Bill No.  
2223, H.D. 1, Regular Session of 2024 (HB 2223), the proposed



coverage was only for cases where biomarker testing was deemed medically necessary. Your Committee believes that, given the diverse and beneficial ways biomarker tests may be used in clinical practice, including disease screening tests and predictive tests, biomarker testing should not be limited solely to cases of medical necessity. This measure therefore requests the Auditor to conduct a statutorily required impact assessment report on the social and financial effects of the mandated health insurance coverage for biomarker testing as proposed by House Bill No. 553, Regular Session of 2025.

As affirmed by the record of votes of the members of your Committee on Health that is attached to this report, your Committee concurs with the intent and purpose of H.C.R. No. 35 and recommends that it be referred to your Committee on Finance.

Respectfully submitted on  
behalf of the members of the  
Committee on Health,

  
\_\_\_\_\_  
GREG TAKAYAMA, Chair



Ms. A. 9.2.15.25

Ms. A. 9.2. 1525

Ms. A. 9.2. 1525